Recent Updates
Recently added Catalysts
PPBT

Kitov Pharmaceuticals Holdings Ltd. (the " Company ") In accordance with Section 318(b) of the Israeli Companies Law, 1999, and Regulation 3(b) of the Israeli Companies Regulations (Merger), 2000, the Company hereby noti

Key Takeaway: Kitov Pharmaceuticals Holdings Ltd. In accordance with Section 318(b) of the Israeli Companies Law, 1999, and Regulation 3(b) of the Israeli Companies Regulations (Merger), 2000, the Company hereby notifies its creditors that on September 28, 2017, the Company has filed with t

Full Press Release Details

Kitov Pharmaceuticals Holdings Ltd.
In accordance with Section 318(b) of the Israeli Companies Law,
1999, and Regulation 3(b) of the Israeli Companies Regulations (Merger), 2000, the Company hereby notifies its creditors that on
September 28, 2017, the Company has filed with the Israeli Registrar of Companies a merger proposal for the merger of Kitov Pharmaceuticals
Ltd., a private company incorporated in Israel, with and into the Company (the "Merger").
Upon the completion of the Merger, Kitov Pharmaceuticals Ltd.
shall merge with and into the Company and be terminated without liquidation.
The merger proposal filed by the Company is available for review
at the offices of the Israeli Registrar of Companies, as well as at the Company's offices at One Azrieli Center, Round Tower,
19th Floor, Tel-Aviv, Israel, during 9:00 -17:00 on Sundays through Thursdays (by scheduling in advance at +972-3-9333121).
Respectfully,
Kitov Pharmaceuticals Holdings Ltd.
Kitov Pharmaceuticals Ltd.
In accordance with Section 318(b) of the Israeli Companies Law,
1999, and Regulation 3(b) of the Israeli Companies Regulations (Merger), 2000, the Company hereby notifies its creditors that on
September 28, 2017, the Company has filed with the Israeli Registrar of Companies a merger proposal for the merger of the Company
with and into the Kitov Pharmaceuticals Holdings Ltd., a public company incorporated in Israel listed on the Tel Aviv Stock Exchange
and the NASDAQ, and the sole shareholder of the Company, (the "Parent Company" and the "Merger",
Upon the completion of the Merger, the Company shall merge with
and into the Parent Company and be terminated without liquidation.
The merger proposal filed by the Company is available for review
at the offices of the Israeli Registrar of Companies, as well as at the Company's offices at One Azrieli Center, Round Tower,
19th Floor, Tel-Aviv, Israel, during 9:00-17:00 on Sundays through Thursdays (by scheduling in advance at +972-3-9333121).
Respectfully,
Kitov Pharmaceuticals Ltd.
Last updated: Sep 28, 2017